Recent Highlights

The trial of a ground-breaking skin cancer drug has begun in Manchester and London. Doctors at The Royal Marsden and The Christie have treated the first patients with a new “resistance-busting” panRAF inhibitor following the announcement of an international consortium to develop the drug.

Our researchers have recently explored the potential to genetically profile womb cancer. As part of an international study, the team showed that it was possible to detect subgroups in high-risk disease and use this classification to predict patient relapse and identify treatment options.